Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, Rodriguez-Bada JL, Alvarez-Lafuente R, Arroyo R, Quintana E, Ramió-Torrentà L, Alonso A, Leyva L, Fernández O, Oliver-Martos B. Aliaga-Gaspar P, et al. Among authors: hurtado guerrero i. Front Immunol. 2021 Dec 16;12:778204. doi: 10.3389/fimmu.2021.778204. eCollection 2021. Front Immunol. 2021. PMID: 34975865 Free PMC article.
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Órpez-Zafra T, et al. Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. Mult Scler. 2017. PMID: 27613121
Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.
Marin-Bañasco C, Benabdellah K, Melero-Jerez C, Oliver B, Pinto-Medel MJ, Hurtado-Guerrero I, de Castro F, Clemente D, Fernández O, Martin F, Leyva L, Suardíaz M. Marin-Bañasco C, et al. Among authors: hurtado guerrero i. Br J Pharmacol. 2017 Feb;174(3):238-253. doi: 10.1111/bph.13674. Epub 2017 Jan 12. Br J Pharmacol. 2017. PMID: 27882538 Free PMC article.
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.
Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, Fernández Ó, Leyva L, Oliver-Martos B. Hurtado-Guerrero I, et al. PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017. PLoS One. 2017. PMID: 28103257 Free PMC article.
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.
Hurtado-Guerrero I, Hernáez B, Pinto-Medel MJ, Calonge E, Rodriguez-Bada JL, Urbaneja P, Alonso A, Mena-Vázquez N, Aliaga P, Issazadeh-Navikas S, Pavia J, Leyva L, Alcamí J, Alcamí A, Fernández Ó, Oliver-Martos B. Hurtado-Guerrero I, et al. J Clin Med. 2020 Mar 31;9(4):959. doi: 10.3390/jcm9040959. J Clin Med. 2020. PMID: 32244308 Free PMC article.
Skin Phototype Could Be a Risk Factor for Multiple Sclerosis.
Urbaneja P, Hurtado-Guerrero I, Hernández MÁ, Oliver-Martos B, Oreja-Guevara C, Ortega-Pinazo J, Alonso A, Barón-López FJ, Leyva L, Fernández Ó, Pinto-Medel MJ. Urbaneja P, et al. Among authors: hurtado guerrero i. J Clin Med. 2020 Jul 26;9(8):2384. doi: 10.3390/jcm9082384. J Clin Med. 2020. PMID: 32722577 Free PMC article.
15 results